Merck Nabs Partial Win In Vioxx Securities Fraud Row
A New Jersey federal judge ruled Wednesday that a class alleging securities fraud could not prove Merck & Co. Inc. misrepresented Vioxx's heart attack risks at least prior to a study...To view the full article, register now.
Already a subscriber? Click here to view full article